Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 12/20 | 0.55 |
| ▸ | NQO1 | P15559 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426684 | 0.88 | CYP19A1 (0.57) | CYP19A1ESR2ESR1NQO1 | |
| SCHEMBL5422463 | 0.88 | CYP19A1 (0.52) | CYP19A1ESR2ESR1NQO1 | |
| SCHEMBL5428058 | 0.87 | CYP19A1 (0.81) | CYP19A1ESR2ESR1NQO1MAPT | |
| SCHEMBL4639676 | 0.87 | CYP19A1 (0.58) | CYP19A1ESR2ESR1NQO1 | |
| SCHEMBL4639584 | 0.83 | ESR1 (0.54) | CYP19A1ESR2ESR1 | |
| SCHEMBL5426736 | 0.82 | ESR1 (0.57) | CYP19A1ESR1 | |
| SCHEMBL5142252 | 0.81 | CYP19A1 (0.74) | CYP19A1ESR2ESR1NQO1VKORC1 | |
| SCHEMBL6153596 | 0.81 | CYP19A1 (0.51) | CYP19A1ESR2ESR1 | |
| SCHEMBL6818924 | 0.79 | ESR1 (0.51) | CYP19A1ESR1NQO1 | |
| SCHEMBL503003 | 0.79 | ESR1 (0.58) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667999-A4 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070191343-A1 | 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191343-A1 | 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-7247646-B2 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247646-B2 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247646-B2 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070123511-A1 | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer | SIGNAL PHARMACEUTICALS LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123511-A1 | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer | SIGNAL PHARMACEUTICALS LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| WO-2007002272-A1 | BENZOPYRANONE COMPOUNDS FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1667999-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050137231-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-06-23 | — | — | US | disclosed |
| WO-2005028472-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1497277-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | NOVARTIS AG (CH) | 2004-05-13 | — | — | US | disclosed |
| WO-2003089422-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-6620838-B1 | Anticarcinogenic, antimestasis, and antiarthritic agents; osteoporosis and endometriosis treatment | SIGNAL PHARMACEUTICALS, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137231-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR1, ESR2, ESRRG | CYP19A1 17/4885ESR2 2/4885ESR1 1/4885 |
| US-20070123511-A1 | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer | BRCA1, RB1, TP53 | CYP19A1 23/4885ESR2 515/4885ESR1 343/4885 |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | ESR2, CYP19A1, ESRRA | CYP19A1 2/4885ESR2 1/4885ESR1 4/4885 |
| US-20070191343-A1 | 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith | CYP3A43, CYP2D6, CYP2J2 | CYP19A1 44/4885ESR2 406/4885ESR1 697/4885 |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR2, ESRRA, ESR1 | CYP19A1 6/4885ESR2 1/4885ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.